Market research
SPRY ARS Pharmaceuticals, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 532M
- P/E ratio
- Not available
- Analyst target
- 23.25
- Dividend yield
- Not available
- Beta
- 0.97
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US82835W1080
- Market cap
- 532M
- P/E ratio
- Not available
- Analyst target
- 23.25
- Dividend yield
- Not available
- Beta
- 0.97
About
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the SPRY discussion.
No comments yet
Start a focused discussion about SPRY.